Daniela Nissani
Inglewood, CANPI 1982381539
Payments from drug & device makers
Across 259 payments — averaging $22.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$999
- Johnson & Johnson$949
- UCB, Inc.$661
- Novartis$396
- Lilly USA, LLC$389
- plus $1K from 9 others
What the payments were for
- Food & beverage$5,820100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $1,174 |
| Amgen | 51 | $999 |
| Johnson & Johnson | 34 | $949 |
| UCB, Inc. | 26 | $661 |
| Novartis | 18 | $396 |
| Lilly USA, LLC | 15 | $389 |
| Mallinckrodt Hospital Products Inc. | 16 | $366 |
| ANI Pharmaceuticals, Inc. | 15 | $309 |
| AstraZeneca(2 entities) | 7 | $177 |
| Pfizer | 5 | $145 |
| Boehringer Ingelheim | 3 | $80 |
| Aurinia Pharma U.S., Inc. | 3 | $75 |
| Radius Health, Inc. | 2 | $40 |
| Sanofi | 1 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$150
- Tremfya$117
- SIMPONI ARIA$117
- Rinvoq$107
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.